Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZYUS Life SciencesTSXV:ZYUS 16 PS Ratio is 82.50 as of Aug. 03, 2026, which is 27% below its 10-year median of 112.50. GuruFocus rates TSXV:ZYUS with a GF Score™ of 16/100. The stock has 7 warning signs investors should review. Among 954 Drug Manufacturers companies, ZYUS Life Sciences ranks worse than 97.38% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, ZYUS Life Sciences's share price is C$0.495.
ZYUS Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was C$0.01. Hence, ZYUS Life Sciences's PS Ratio for today is 82.50.
Good Sign:
ZYUS Life Sciences Corp stock PS Ratio (=82.5) is close to 5-year low of 76.25.
The historical rank and industry rank for ZYUS Life Sciences's PS Ratio or its related term are showing as below:
TSXV:ZYUS'
s PS Ratio Range Over the Past 10 Years
Min: 76.25 Med: 112.5 Max: 432.5
Current: 82.5
During the past 5 years, ZYUS Life Sciences's highest PS Ratio was 432.50. The lowest was 76.25. And the median was 112.50.
TSXV:ZYUS's PS Ratio is ranked worse than 97.38% of 954
companies
in the Drug Manufacturers industry
Industry Median: 2.305
vs TSXV:ZYUS: 82.50
During the past 5 years, ZYUS Life Sciences's highest 3-Year average Revenue per Share Growth Rate was 32.60% per year. The lowest was 7.70% per year. And the median was 20.15% per year.
ZYUS Life Sciences (TSXV:ZYUS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
ZYUS Life Sciences PS Ratio Related Terms
ZYUS Life Sciences PS Ratio Historical Data
* Premium members only.
The historical data trend for ZYUS Life Sciences's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:ZYUS vs RMTI, BTAI, MRMD: PS Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ZYUS Life Sciences PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where ZYUS Life Sciences's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
ZYUS Life Sciences's Share Price of today is C$0.495. ZYUS Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
ZYUS Life Sciences (TSXV:ZYUS) has a PS Ratio of 82.50 as of Aug. 03, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ZYUS Life Sciences and its competitors. This is 27% below median its historical median of 112.50. Over the past decade, ZYUS Life Sciences' PS Ratio has ranged from 76.25 to 432.50. According to the industry distribution chart, ZYUS Life Sciences ranks #929 out of 954 companies in the Drug Manufacturers industry, placing it in the top 97.4%.
Is ZYUS Life Sciences' PS Ratio too high?
ZYUS Life Sciences' current PS Ratio of 82.50 is 27% below median its 10-year median of 112.50. Over the past 10 years, this metric has ranged from a low of 76.25 to a high of 432.50. The Drug Manufacturers industry median PS Ratio is 2.31. ZYUS Life Sciences' value of 82.50 is 3479.2% above this industry median. Based on the distribution chart, ZYUS Life Sciences ranks #929 out of 954 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ZYUS Life Sciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does ZYUS Life Sciences' PS Ratio compare to RMTI and BTAI?
According to the Drug Manufacturers industry distribution chart, ZYUS Life Sciences ranks #929 out of 954 companies for PS Ratio. This places ZYUS Life Sciences in the lower half of its industry. The industry median PS Ratio is 2.31. ZYUS Life Sciences' value of 82.50 is 3479.2% above this benchmark. Historically, ZYUS Life Sciences' own PS Ratio has ranged from 76.25 to 432.50 over the past decade. While the company's 10-year median is 112.50 vs. the industry median of 2.31, ZYUS Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.31, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ZYUS Life Sciences's current PS Ratio of 82.50 is 3479.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ZYUS Life Sciences and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ZYUS Life Sciences's current PS Ratio is 82.50, which is 27% below median its own 10-year median of 112.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
ZYUS Life Sciences (TSXV:ZYUS) has a current PS Ratio of 82.50. The current PS Ratio is 82.50, which is 27% below median its 10-year median of 112.50 and 3479.2% above the Drug Manufacturers industry median of 2.31. ZYUS Life Sciences' overall GF Score™ is 16/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For ZYUS Life Sciences (TSXV:ZYUS), the current PS Ratio is 82.50 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
16GF Score
Get the complete analysis for TSXV:ZYUS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:ZYUS has been successfully added to your 
